Capricor Therapeutics inc (CAPR) - News Archive

Investors on Alert: Capricor Therapeutics Faces Class Action Amid Declining Revenue and Controversial Phase 2 Trial DataIn a significant development for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clas...

Investor Concerns Mount as Class Action Lawsuits Emerge Against Capricor Therapeutics In the fast-paced world of biotechnology, companies often attract substantial investments due to their innovative approaches to healt...

In a notable development for investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR), the Rosen Law Firm has issued an important reminder regarding a forthcoming deadline for those who have sustained significant financi...

Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on cardiac and rare disease therapies, should be aware of pressing legal and regulatory matters concerning the company. Amid ongoi...

In the ever-shifting landscape of healthcare investment, few stories encapsulate both the promise and peril of biotech ventures quite like that of Capricor Therapeutics, Inc. Following a recent announcement from Bronste...

Investor Vigilance: Pomerantz Law Firm Investigates Potential Claims Against Capricor Therapeutics, Inc. In an era where biotechnology firms continuously transform healthcare paradigms, the integrity of their financial...

Innovative Paths in Treating Duchenne Muscular Dystrophy: An Update on Capricor Therapeutics Journey with Deramiocel The field of biotechnology remains at the forefront of innovative healthcare solutions, particularly w...

Capricor Therapeutics Advances Toward a Milestone in Duchenne Muscular Dystrophy Treatment with FDA Priority ReviewCapricor Therapeutics has taken a significant step forward in the field of genetic medicine, announcing...

Capricor Therapeutics, a biotechnology company focused on developing innovative cell and exosome-based therapeutics for rare diseases, has announced significant regulatory progress for its Duchenne Muscular Dystrophy (D...

Pioneering Progress: Capricor Therapeutics Advances Toward Approval of Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy Capricor Therapeutics, a biopharmaceutical company at the forefront of regenerative medici...

Capricor Therapeutics Closes Successful $86.3 Million Public Offering, Paving the Way for Rare Disease InnovationOn October 18, 2024, Capricor Therapeutics Inc. a biotechnology company based in San Diego specializing in...

Capricor Therapeutics Secures $75 Million Public Offering Amid Promising Advances in Rare Disease TreatmentSAN DIEGO In a significant move for its financial and research agenda, Capricor Therapeutics (NASDAQ: CAPR) has...

Outline of Facts:1. Public Offering Announcement: - Capricor Therapeutics (NASDAQ: CAPR), a San Diego-based biotechnology company, announced the commencement of a proposed underwritten public offering of its common stoc...

Innovative Therapies in Neuromuscular Disorders: Capricor Therapeutics Presents Promising Long-term Data on Deramcicel for Duchenne Muscular Dystrophy In a groundbreaking presentation at the 2024 World Muscle Society Co...

In the ever-evolving landscape of biopharmaceutical innovation, hope often hinges on the breakthroughs of tomorrow. Capricor Therapeutics, a pioneering company in the realm of advanced therapeutic modalities, has announ...

In the hallowed halls of medical progress, a luminous beacon has emerged, heralding a momentous stride in the realm of biopharmaceutical innovation. Capricor Therapeutics, an esteemed purveyor of advanced therapeutic mo...

Capricor Therapeutics Pioneers European Expansion with Nippon Shinyaku Partnership for Duchenne Muscular Dystrophy Treatment Capricor Therapeutics, a biotechnology firm specializing in the discovery, development, and co...

Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 IndexesSan Diego-based biotechnology company, Capricor Therapeutics (NASDAQ: CAPR), has announced its inclusion in the prestigious Russell 2000 Index and t...

In recent announcements, Capricor Therapeutics shares exciting developments regarding their experimental therapy, CAP-1002, for the treatment of Duchenne Muscular Dystrophy (DMD). The company reports positive outcomes i...

SAN DIEGO, June 25, 2024 - Capricor Therapeutics, a leading biotechnology company focused on regenerative medicine, has announced a significant milestone in the development of a groundbreaking treatment for Duchenne Mus...